ABOUT 2nd_OCIF
​> AGENDA​
> REGISTRATION
​> ATTENDEES​
​> PRESENTERS
​> SPONSORS​
​> SUPPORTERS​
​​> NETWORKING
> VENUE
> ACCOMMODATION

> ABOUT LAST BOIF

20-minute presenters:

​Amgen, Inc.
[NASDAQ: AMGN]

Amgen discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines, helping make people’s lives easier, fuller, and longer.
​
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat heart disease, obesity and obesity-related conditions, rare diseases, inflammatory conditions, and cancer.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

www.amgen.com

​Eos SENOLYTIX, inc.

Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos’s lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the “Δψm”. These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and (2) the profound elimination of senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects. Extensive preclinical studies suggest the MitoXcel™ platform may be a broad gerotherapeutic that improves body composition, increasing lean muscle mass, and enhancing physical function in aging animals. By targeting fundamental processes driving aging and aging-related diseases, Eos SENOLYTIX is pursuing a unique therapeutic opportunity to intervene in the aging process in ways that were once thought impossible. Eos SENOLYTIX is headquartered in Houston, Texas and operates within the broader SENOTHERAPEUTIX/GEROTHERAPEUTIX group of longevity companies, which focuses on developing therapeutics targeting fundamental drivers of aging to improve healthspan and lifespan.

www.eossenolytix.com

10-minute presenters:

​Alphala Co., Ltd

Alphala Co., Ltd. is a clinical-stage biotechnology company advancing ALP001E, a novel oral small molecule designed to directly target insulin resistance, the underlying driver of type 2 diabetes and cardiometabolic diseases. In early human studies, ALP001E demonstrated rapid and substantial improvements in insulin resistance and glycemic control, with a profile distinct from existing therapies. By addressing the root cause rather than downstream symptoms, Alphala aims to redefine the treatment paradigm beyond GLP-1–based approaches and unlock new opportunities across the broader metabolic disease spectrum.

www.alphala-group.com

​Alveus Therapeutics, Inc. 

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
​
www.alveustx.com

MitoRx Therapeutics Limited

MitoRx Therapeutics' first-in-class mitochondrial metabolic modulation platform has the potential to address obesity and other key cardiometabolic diseases, focusing first on obesity.  MitoRx directs small molecules targeted to the mitochondria which have been demonstrated to be both anti-obesogenic and preserve lean mass in multiple metabolic disease models, result published in oral presentations and posters at ADA 2025, EASD 2025 and ECO 2025.

Based in Oxford and Cambridge, UK, MitoRx is developing two core programs in obesity to progress to the clinic including intermittent injectable and an orally administered programs.

MitoRx Therapeutics' technology builds on over a decade’s worth of academic research by one of the pioneers of mitochondrial-targeting technology, Prof Matt Whiteman PhD, Professor of Experimental Therapeutics at the University of Exeter, who has published over twenty papers demonstrating pharmacological utility of mitochondrial-targeted tool compounds in multiple in vivo models.

www.mitorxtherapeutics.com

​Nitinotes Surgical

Nitinotes is a medical technology company advancing minimally invasive solutions for obesity and metabolic disease. Its proprietary platform, EndoZip™, is the first automated endoscopic suturing system designed to simplify and standardize endoscopic sleeve gastroplasty (ESG), enabling a single-operator workflow and improving procedural efficiency and reproducibility. With CE Mark approval and early commercial adoption underway in Europe, Nitinotes is expanding access to scalable, procedure-based interventions that complement pharmacotherapy and surgery—supporting a more personalized, continuum-driven approach to obesity care.​

www.nitinotesurgical.com

PriveBio, Inc.

PriveBio is a precision medicine biotech focused on developing first-in-class therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases (obesity, heart failure, NASH/MASH, and chronic kidney diseases), prosecuting validated targets from human proteo-genomics data across very large human datasets.

www.privebio.com

​Rivus Pharmaceuticals

Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health.

www.rivuspharma.com